



Clinical Guidelines
for the use of
Blood products
in South Africa
2nd Edition

Edited by the Medical Directors of the
South African National Blood Service
2001

Sponsored by Adcock Ingram Critical Care and Sterilab

TABLE OF CONTENTS

Disclaimer	v
FOREWORD	vi
SECTION 1 INTRODUCTION	1
SECTION 2 RISKS OF BLOOD TRANSFUSION	2
1 HAEMOLYTIC TRANSFUSION REACTIONS	2
2 TRANSMISSIBLE DISEASE AND DONOR SELECTION	2
a) <i>Health screening</i>	2
b) <i>Testing</i>	2
c) <i>Look back programme</i>	3
3 ADDITIONAL SAFETY MEASURES	3
SECTION 3 ALTERNATIVE TRANSFUSION OPTIONS	4
1 AUTOLOGOUS DONATION	4
2 DESIGNATED DONATION	4
SECTION 4 LEGAL ASPECTS OF TRANSFUSION	6
SECTION 5 ORDERING AND ADMINISTRATION OF BLOOD	8
1 IDENTIFICATION AND VERIFICATION	8
a) <i>The Unit</i>	9
b) <i>The patient</i>	9
2 ASEPTIC TECHNIQUE	10
3 MONITORING THE PATIENT	10
4 SPECIAL PRECAUTIONS	10
a) <i>Rate of transfusion</i>	10
b) <i>Filters</i>	11
c) <i>Temperature of the blood</i>	11
d) <i>Additives</i>	12
SECTION 6 RED CELL PRODUCTS	13
1 WHOLE BLOOD	13
a) <i>Indications</i>	13
2 RED CELL CONCENTRATES (RCC)	14
a) <i>Indications</i>	14
3 OTHER RED CELL PRODUCTS	15
4 IRRADIATED BLOOD PRODUCTS	17
SECTION 7 PAEDIATRIC TRANSFUSION PRODUCTS	18
1 TESTING	18
2 PRETRANSFUSION TESTING FOR NEONATES	18

3	OTHER CONSIDERATIONS	19
4	INDICATIONS FOR RED CELL TRANSFUSION	19
	<i>a) Top-up Transfusion</i>	19
	<i>b) Exchange Transfusion</i>	20
5	TREATMENT OF HYPOVOLAEMIC SHOCK.	20
6	SPECIFIC PAEDIATRIC PRODUCTS	21
	<i>a) Red cell concentrate</i>	21
	<i>b) FFP</i>	21
7	LIMITED DONOR EXPOSURE PROGRAMME	21
	SECTION 8 LEUCOCYTE DEPLETED BLOOD COMPONENTS	22
	1 DEFINITION	22
	2 INDICATIONS FOR LEUCOCYTE DEPLETED COMPONENTS	23
	SECTION 9 PLATELETS	24
	1 INDICATIONS FOR PLATELET TRANSFUSIONS	24
	2 PLATELET PRODUCTS	25
	<i>a) Random donor platelets</i>	25
	<i>b) Apheresis single donor platelet concentrate</i>	26
	3 GENERAL RULES REGARDING PLATELET TRANSFUSION	26
	4 MONITORING PATIENT	27
	SECTION 10 PLASMA DERIVED PRODUCTS	29
	1 FRESH FROZEN PLASMA	29
	2 SPECIFIC COAGULATION FACTOR PRODUCTS	32
	<i>a) Dosage Schedule</i>	33
	3 HAEMOPHILIA A	33
	4 VON WILLEBRAND DISEASE (VWD)	35
	<i>a) Dosage</i>	35
	5 HAEMOPHILIA B	35
	6 HYPOFIBRINOGENAEMIA	36
	7 OTHER PLASMA PRODUCTS	36
	<i>a) Albumin 20% Solution</i>	36
	<i>b) Stabilised Human Serum</i>	37
	8 IMMUNOGLOBULIN THERAPY	38
	SECTION 11 TRANSFUSION REACTIONS	42
	1 MONITORING	42
	2 INVESTIGATION	43
	3 TYPES OF REACTIONS	44
	SECTION 12 TRANSFUSION REACTION REPORTS	47
	SECTION 13 MAXIMUM SURGICAL BLOOD ORDERING SCHEDULE (MSBOS)	48
	SECTION 14 CONTACT TELEPHONE NUMBERS	54

TABLES

Table 1: Red Cell Products	15
Table 2: Clinical Indications for other Red Cell Products	16
Table 3: Thrombocytopenia and Bleeding	25
Table 4: Platelet Information and Dosage Guidelines	27
Table 5: Fresh Frozen Plasma	29
Table 6: Average Levels of Coagulation Factor in a Unit of FFP	30
Table 7: Solutes in FFP	30
Table 8: Clinical Indications for FFP	31
Table 9: Coagulation Concentrates	32
Table 10: Clinical Indications for Coagulation Concentrates	32
Table 11: Haemophilia A Target Factor Levels	33
Table 12: Empirical Dosage Regimen if Monitoring is not Available	34
Table 13: Haemophilia B Target Factor Levels	35
Table 14: Hypofibrinogenaemia Treatment Guidelines	36
Table 15: Indications for Albumin	36
Table 16: Composition of Stabilised Human Serum	37
Table 17: Indications for Intravenous Immunoglobulins	39
Table 18: Intramuscular Immunoglobulin Preparations	39
Table 19: Intravenous Immunoglobulin	41
Table 20: Signs and Symptoms that are Highly Suggestive of a Serious Transfusion Reaction	43
Table 21: Potentially Life Threatening Reactions	44
Table 22: Less serious reactions	46
Table 23: Blood Ordering Schedule as devised by Groote Schuur Hospital	48
Table 24: Definitions of Blood Products, Blood Components and Plasma Derivatives	51
Table 25: Terms Associated with Ordering Blood	52
Table 26: List of products for which the National Bioproducts Institute is the applicant	53